Porres J C, Carreño V, Ruíz M, Marrón J A, Bartolomé J
Gastroenterology Department, Fundación Jiménez Díaz, Madrid, Spain.
J Hepatol. 1989 May;8(3):351-7. doi: 10.1016/0168-8278(89)90034-2.
In different trials, a total of 46 adults and 12 children suffering from chronic hepatitis B virus (HBV) and who were HBV-DNA- and HBeAg-positive were treated with recombinant interferon-alpha (rIFN alpha)-2A. The interferon was administered intramuscularly in different doses ranging from 1.5 MU to 20 MU/m2 of body surface, two or three times weekly during 4-6 months. Specific detection of anti-IFN antibodies by enzymoimmunoassay (EIA), radioimmunoassay (RIA) and biological assays during treatment and follow-up periods were performed. None of the children developed anti-IFN antibodies. During therapy, 12 adult patients (26%) were found to have anti-IFN antibodies. A total of five patients became HBV-DNA-negative during therapy, but in three cases a reactivation of viral replication occurred subsequently. In these three patients, the appearance of anti-IFN antibodies occurred prior to or at the same time as HBV-DNA loss. The other seven patients did not respond to therapy. In conclusion, the development of anti-IFN antibodies during rIFN alpha treatment of chronic hepatitis B may modify the response to therapy, especially if they appear before HBV-DNA negativization.
在不同试验中，共有46名成人和12名儿童患有慢性乙型肝炎病毒（HBV），且HBV-DNA和HBeAg呈阳性，他们接受了重组干扰素α（rIFNα）-2A治疗。干扰素以不同剂量进行肌肉注射，剂量范围为1.5 MU至20 MU/m²体表面积，每周注射两到三次，持续4至6个月。在治疗期间和随访期间，通过酶免疫测定（EIA）、放射免疫测定（RIA）和生物学测定对抗干扰素抗体进行了特异性检测。儿童均未产生抗干扰素抗体。在治疗期间，发现12名成年患者（26%）产生了抗干扰素抗体。共有5名患者在治疗期间HBV-DNA转为阴性，但其中3例随后出现病毒复制重新激活。在这3名患者中，抗干扰素抗体在HBV-DNA转阴之前或同时出现。其他7名患者对治疗无反应。总之，在慢性乙型肝炎的rIFNα治疗期间，抗干扰素抗体的产生可能会改变治疗反应，特别是如果它们在HBV-DNA转阴之前出现。
